Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
2008 1
2014 2
2015 1
2016 1
2017 4
2019 5
2020 2
2021 7
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Advances in Chemical Constituents, Clinical Applications, Pharmacology, Pharmacokinetics and Toxicology of Erigeron breviscapus.
Wu R, Liang Y, Xu M, Fu K, Zhang Y, Wu L, Wang Z. Wu R, et al. Front Pharmacol. 2021 Sep 2;12:656335. doi: 10.3389/fphar.2021.656335. eCollection 2021. Front Pharmacol. 2021. PMID: 34539390 Free PMC article. Review.
., belonging to Compositae and first published in Materia Medica of South Yunnan by Lan Mao in the Ming Dynasty (1368 AD-1644 AD), is included in Medicinal Materials and Decoction Pieces of the 2020 edition of the Pharmacopeia of the People's Republic of China. ...
., belonging to Compositae and first published in Materia Medica of South Yunnan by Lan Mao in the Ming Dynasty (1368 AD-1644 …
Association between age and clinical characteristics and outcomes of COVID-19.
Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, Wang L, Zhang L, Li QH, Zhao L, He Y, Gu XL, Ji XB, Li L, Jie ZJ, Li Q, Li XY, Lu HZ, Zhang WH, Song YL, Qu JM, Xu JF; Shanghai Clinical Treatment Experts Group for COVID-19. Liu Y, et al. Eur Respir J. 2020 May 27;55(5):2001112. doi: 10.1183/13993003.01112-2020. Print 2020 May. Eur Respir J. 2020. PMID: 32312864 Free PMC article.
Bi-Functional Radiotheranostics of 188Re-Liposome-Fcy-hEGF for Radio- and Chemo-Therapy of EGFR-Overexpressing Cancer Cells.
Huang YS, Hsu WC, Lin CH, Lo SN, Cheng CN, Lin MS, Lee TW, Chang CH, Lan KL. Huang YS, et al. Int J Mol Sci. 2021 Feb 14;22(4):1902. doi: 10.3390/ijms22041902. Int J Mol Sci. 2021. PMID: 33672989 Free PMC article.
Fcy-hEGF fusion protein, composed of yeast cytosine deaminase (Fcy) and human EGF (hEGF), is capable of binding to EGFR and enzymatically convert 5-fluorocytosine (5-FC) to 1000-fold toxic 5-fluorocuracil (5-FU), thereby inhibiting the growth of EGFR-expressing tumor cells …
Fcy-hEGF fusion protein, composed of yeast cytosine deaminase (Fcy) and human EGF (hEGF), is capable of binding to EGFR and enzymatically co …
Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells.
Lan KH, Tsai CL, Chen YY, Lee TL, Pai CW, Chao Y, Lan KL. Lan KH, et al. Biochem Biophys Res Commun. 2021 Dec 10;582:137-143. doi: 10.1016/j.bbrc.2021.09.078. Epub 2021 Oct 1. Biochem Biophys Res Commun. 2021. PMID: 34710829
Here, we adopted a prodrug system that uses 5-fluorocytosine (5-FC) and a HER2-targeting scaffold protein, Z(HER2:2891), fused with yeast cytosine deaminase (Fcy) to target HER2-overexpressing cancer cells and to convert 5-FC to a significantly more toxic chemotherapeutic, 5-fluo …
Here, we adopted a prodrug system that uses 5-fluorocytosine (5-FC) and a HER2-targeting scaffold protein, Z(HER2:2891), fused with yeast cy …
29 results